Arbutus Biopharma Corp (ABUS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
40/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseABUS / S&P 6.67% / 15.20% |
WinABUS / S&P 1078.78% / 15.00% |
LoseABUS / S&P -372.41% / 50.40% |
| 2026-Q11/3 |
LoseABUS / S&P -6.44% / -4.33% |
WinABUS / S&P 2889.93% / 11.30% |
LoseABUS / S&P -302.44% / 27.70% |
| 2025-Q42/3 |
WinABUS / S&P 5.95% / 2.65% |
WinABUS / S&P 128.21% / 9.00% |
LoseABUS / S&P -55.26% / 13.40% |
| 2025-Q32/3 |
WinABUS / S&P 46.93% / 8.12% |
WinABUS / S&P 116.64% / 4.61% |
LoseABUS / S&P -46.51% / 13.45% |
| 2025-Q21/3 |
LoseABUS / S&P -11.46% / 10.94% |
WinABUS / S&P 53.23% / 4.83% |
LoseABUS / S&P -35.56% / 10.63% |
| 2025-Q11/3 |
WinABUS / S&P 6.73% / -4.27% |
LoseABUS / S&P -50.69% / 4.98% |
LoseABUS / S&P -6.82% / 10.57% |
| 2024-Q40/3 |
LoseABUS / S&P -15.06% / 2.41% |
LoseABUS / S&P -65.98% / 5.25% |
LoseABUS / S&P -13.64% / 6.15% |
| 2024-Q31/3 |
WinABUS / S&P 24.60% / 5.89% |
LoseABUS / S&P -69.69% / 5.89% |
LoseABUS / S&P -6.52% / 6.11% |
| 2024-Q21/3 |
WinABUS / S&P 19.77% / 4.28% |
LoseABUS / S&P -57.25% / 5.38% |
LoseABUS / S&P -2.17% / 5.12% |
| 2024-Q10/3 |
LoseABUS / S&P 3.20% / 10.56% |
LoseABUS / S&P -60.80% / 5.71% |
LoseABUS / S&P -4.35% / 5.59% |
| 2023-Q41/3 |
WinABUS / S&P 23.15% / 11.69% |
LoseABUS / S&P -53.51% / 6.81% |
LoseABUS / S&P -6.38% / 7.78% |
| 2023-Q31/3 |
LoseABUS / S&P -11.74% / -3.27% |
LoseABUS / S&P -38.19% / 7.52% |
WinABUS / S&P -4.17% / -5.03% |
| 2023-Q20/3 |
LoseABUS / S&P -24.09% / 8.74% |
LoseABUS / S&P -29.47% / 9.50% |
LoseABUS / S&P -23.33% / -8.57% |
| 2023-Q12/3 |
WinABUS / S&P 30.04% / 7.50% |
WinABUS / S&P 54.39% / 10.77% |
LoseABUS / S&P -36.99% / -15.69% |
| 2022-Q42/3 |
WinABUS / S&P 21.99% / 7.56% |
WinABUS / S&P 255.11% / 11.88% |
LoseABUS / S&P -43.37% / -17.99% |
| 2022-Q31/3 |
LoseABUS / S&P -29.52% / -4.88% |
WinABUS / S&P 253.86% / 13.47% |
LoseABUS / S&P -47.25% / -1.41% |
| 2022-Q22/3 |
WinABUS / S&P -9.06% / -16.10% |
WinABUS / S&P 299.57% / 13.71% |
LoseABUS / S&P -36.17% / 11.04% |
| 2022-Q11/3 |
LoseABUS / S&P -23.39% / -4.60% |
WinABUS / S&P 184.71% / 15.97% |
LoseABUS / S&P -23.96% / 42.23% |
| 2021-Q41/3 |
LoseABUS / S&P -9.32% / 11.03% |
WinABUS / S&P 58.92% / 15.00% |
LoseABUS / S&P -17.00% / 96.40% |
| 2021-Q32/3 |
WinABUS / S&P 41.58% / 0.58% |
WinABUS / S&P 65.44% / 10.77% |
LoseABUS / S&P ABUS unavailable / 69.42% |
| 2021-Q21/3 |
LoseABUS / S&P -9.01% / 8.55% |
WinABUS / S&P 8.68% / 6.58% |
LoseABUS / S&P ABUS unavailable / 51.81% |
| 2021-Q11/3 |
LoseABUS / S&P -6.20% / 6.17% |
WinABUS / S&P 10.45% / -1.06% |
LoseABUS / S&P ABUS unavailable / 7.39% |
| 2020-Q42/3 |
WinABUS / S&P 13.42% / 12.15% |
WinABUS / S&P 15.02% / -3.72% |
LoseABUS / S&P ABUS unavailable / -33.42% |
| 2020-Q31/3 |
WinABUS / S&P 71.98% / 8.93% |
LoseABUS / S&P -29.77% / -2.04% |
LoseABUS / S&P ABUS unavailable / -27.10% |
| 2020-Q22/3 |
WinABUS / S&P 80.20% / 20.54% |
WinABUS / S&P 5.59% / -0.46% |
LoseABUS / S&P ABUS unavailable / -27.11% |
| 2020-Q10/3 |
LoseABUS / S&P -63.67% / -19.60% |
LoseABUS / S&P -13.28% / 3.47% |
LoseABUS / S&P ABUS unavailable / -14.75% |
| 2019-Q41/3 |
WinABUS / S&P 81.70% / 9.07% |
LoseABUS / S&P -30.31% / 5.36% |
LoseABUS / S&P ABUS unavailable / 2.99% |
| 2019-Q31/3 |
LoseABUS / S&P -26.44% / 1.70% |
WinABUS / S&P 28.67% / 5.02% |
LoseABUS / S&P ABUS unavailable / 0.21% |
| 2019-Q20/3 |
LoseABUS / S&P -41.90% / 4.30% |
LoseABUS / S&P -39.89% / 6.64% |
LoseABUS / S&P ABUS unavailable / 8.65% |
| 2019-Q10/3 |
LoseABUS / S&P -6.53% / 13.65% |
LoseABUS / S&P -33.89% / 8.12% |
LoseABUS / S&P ABUS unavailable / 14.29% |
| 2018-Q40/3 |
LoseABUS / S&P -59.47% / -13.52% |
LoseABUS / S&P -19.39% / 9.05% |
LoseABUS / S&P ABUS unavailable / 18.23% |
| 2018-Q31/3 |
WinABUS / S&P 29.45% / 7.71% |
LoseABUS / S&P -14.68% / 10.21% |
LoseABUS / S&P ABUS unavailable / 19.06% |
| 2018-Q22/3 |
WinABUS / S&P 46.00% / 3.43% |
WinABUS / S&P 553.32% / 9.03% |
LoseABUS / S&P ABUS unavailable / 14.46% |
| 2018-Q11/3 |
LoseABUS / S&P -0.99% / -0.76% |
WinABUS / S&P 959.75% / 7.68% |
LoseABUS / S&P ABUS unavailable / 12.46% |
| 2017-Q41/3 |
LoseABUS / S&P -18.55% / 6.64% |
WinABUS / S&P 617.64% / 7.03% |
LoseABUS / S&P ABUS unavailable / 13.82% |
| 2017-Q31/3 |
WinABUS / S&P 72.22% / 4.48% |
LoseABUS / S&P -37.60% / 5.68% |
LoseABUS / S&P ABUS unavailable / 17.57% |
| 2017-Q21/3 |
WinABUS / S&P 10.77% / 3.09% |
LoseABUS / S&P -88.47% / 4.83% |
LoseABUS / S&P ABUS unavailable / 17.74% |
| 2017-Q11/3 |
WinABUS / S&P 32.65% / 6.07% |
LoseABUS / S&P -94.15% / 3.67% |
LoseABUS / S&P ABUS unavailable / 13.32% |
| 2016-Q40/3 |
LoseABUS / S&P -28.78% / 3.82% |
LoseABUS / S&P -93.59% / 2.09% |
LoseABUS / S&P ABUS unavailable / 7.05% |
| 2016-Q30/3 |
LoseABUS / S&P -1.15% / 3.85% |
LoseABUS / S&P -22.75% / 0.20% |
LoseABUS / S&P ABUS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ABUS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 39.35% | 20.78% |
| Annualized return | 39.35% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ABUS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 50.29% | 83.14% |
| Annualized return | 8.49% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ABUS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 36.41% | 319.30% |
| Annualized return | 3.15% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |